Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III bought 38,300 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $29.02 per share, with a total value of $1,111,466.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Xencor stock traded down $0.15 during mid-day trading on Tuesday, hitting $30.27. 96,145 shares of the company were exchanged, compared to its average volume of 218,691. Xencor Inc has a 1-year low of $27.57 and a 1-year high of $48.38. The firm has a market capitalization of $1.69 billion, a P/E ratio of -23.11 and a beta of 1.40.

A number of research analysts recently commented on XNCR shares. Raymond James started coverage on Xencor in a research note on Thursday, March 14th. They issued an “outperform” rating and a $27.85 target price for the company. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Saturday, December 1st. BidaskClub lowered Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Nomura lowered Xencor from a “neutral” rating to a “reduce” rating and dropped their price objective for the stock from $28.00 to $21.00 in a research note on Friday, February 22nd. Finally, Piper Jaffray Companies increased their price objective on Xencor to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. Xencor currently has a consensus rating of “Buy” and an average price target of $40.43.

Institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. grew its holdings in shares of Xencor by 46.9% during the fourth quarter. Meeder Asset Management Inc. now owns 2,910 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 929 shares during the last quarter. Chartwell Investment Partners LLC grew its holdings in shares of Xencor by 3.2% during the fourth quarter. Chartwell Investment Partners LLC now owns 40,778 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 1,264 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Xencor by 5.4% during the third quarter. Wells Fargo & Company MN now owns 25,710 shares of the biopharmaceutical company’s stock worth $1,002,000 after purchasing an additional 1,310 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Xencor by 8.8% during the fourth quarter. Legal & General Group Plc now owns 18,728 shares of the biopharmaceutical company’s stock worth $678,000 after purchasing an additional 1,517 shares during the last quarter. Finally, Virginia Retirement Systems ET AL grew its holdings in shares of Xencor by 6.9% during the fourth quarter. Virginia Retirement Systems ET AL now owns 24,700 shares of the biopharmaceutical company’s stock worth $893,000 after purchasing an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “John S. Stafford III Acquires 38,300 Shares of Xencor Inc (XNCR) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/john-s-stafford-iii-acquires-38300-shares-of-xencor-inc-xncr-stock/2902518.html.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Article: The Structure of a Futures Contract

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.